Complement Pathway Inhibition Therapy for Neurodegeneration

Cross-Linking Context

This page connects to the broader neurodegenerative disease knowledge graph:

• Diseases: [Alzheimer’s disease](/diseases/alzheimers-disease), [Parkinson’s disease](/diseases/parkinsons-disease), ALS, FTD, [Huntington’s disease](/diseases/huntingtons-disease), PSP, MSA

• Brain regions: [substantia nigra](/brain-regions/substantia-nigra), striatum, motor cortex, hippocampus, frontal cortex

• Cell types: [dopaminergic neurons](/cell-types/mesencephalic-dopaminergic-neurons), [astrocytes](/cell-types/astrocytes), [microglia](/cell-types/microglia), motor neurons, oligodendrocytes

• Proteins/Genes: tau, [alpha-synuclein](/proteins/alpha-synuclein), TDP-43, SNCA, GBA, LRRK2, C9orf72, HTT

• Mechanisms: [neuroinflammation](/mechanisms/neuroinflammation), [mitochondrial dysfunction](/mechanisms/mitochondrial-dysfunction), [lysosomal dysfunction](/mechanisms/lysosomal-dysfunction), [protein aggregation](/mechanisms/protein-aggregation), [oxidative stress](/mechanisms/oxidative-stress), [autophagy](/mechanisms/autophagy), [synaptic dysfunction dysfunction](/mechanisms/synaptic dysfunction-dysfunction)

• Therapeutics: [gene therapy](/therapeutics/gene-therapy-neurodegeneration), ASOs, CRISPR gene editing, deep brain stimulation

• Pathways: complement system, neurotrophic signaling, cell death pathways

Overview

flowchart TD
    COMPLEMENT["COMPLEMENT"] -->|"activates"| ASTROCYTES["ASTROCYTES"]
    COMPLEMENT["COMPLEMENT"] -->|"activates"| C1Q["C1Q"]
    COMPLEMENT["COMPLEMENT"] -->|"activates"| Als["Als"]
    COMPLEMENT["COMPLEMENT"] -->|"activates"| Complement["Complement"]
    COMPLEMENT["COMPLEMENT"] -->|"activates"| MICROGLIA["MICROGLIA"]
    COMPLEMENT["COMPLEMENT"] -->|"therapeutic target"| Als["Als"]
    COMPLEMENT["COMPLEMENT"] -->|"therapeutic target"| Complement["Complement"]
    COMPLEMENT["COMPLEMENT"] -->|"activates"| Aging["Aging"]
    COMPLEMENT["COMPLEMENT"] -->|"activates"| NEUROINFLAMMATION["NEUROINFLAMMATION"]
    COMPLEMENT["COMPLEMENT"] -->|"activates"| Inflammation["Inflammation"]
    COMPLEMENT["COMPLEMENT"] -->|"activates"| Alzheimer["Alzheimer"]
    COMPLEMENT["COMPLEMENT"] -->|"activates"| Neurodegeneration["Neurodegeneration"]
    COMPLEMENT["COMPLEMENT"] -->|"associated with"| Complement["Complement"]
    COMPLEMENT["COMPLEMENT"] -->|"regulates"| Complement["Complement"]
    style complement fill:#4fc3f7,stroke:#333,color:#000

Complement Pathway Inhibition Therapy targets the classical complement cascade — specifically C1q, C3, and the membrane attack complex (MAC/C5b-C9) — to prevent pathological synaptic dysfunction pruning, neuroinflammation, and myelin damage across Alzheimer’s disease, Parkinson’s disease, ALS, and aging. The complement system normally functions in synaptic dysfunction refinement during development, but in neurodegenerative disease, this pathway is pathologically reactivated, driving excessive synapse elimination that correlates directly with cognitive decline

This therapeutic approach is the first to simultaneously address three complement-mediated damage pathways: C1q-mediated synaptic dysfunction tagging, C3a/C3b-mediated microglial phagocytosis via CR3 receptor, and C5b-C9 MAC-mediated direct neuronal lysis.

Mechanistic Rationale

The Complement Cascade in Neurodegeneration

The complement system comprises over 50 proteins organized into three activation pathways (classical, lectin, alternative). In neurodegeneration, the classical pathway — initiated by C1q binding to vulnerable synapses — is the primary driver of pathological synapse loss^{2C1q labels synapses for elimination in the adult brain2017 · Nature · PMID 29197116Open reference3Anti-C1q blockade prevents synapse elimination in a mouse model of [Alzheimer's disease](/diseases/alzheimers-disease)2020 · Nature Neuroscience · PMID 32029650Open reference}.

Pathological cascade:

1. C1q binding — In AD, Aβ oligomers and tau pathology expose phosphatidylserine and other “eat me” signals on vulnerable synapses, triggering C1q recruitment^{1Complement and [microglia](/cell-types/microglia) mediate early synapse loss in Alzheimer mouse models2016 · Science · PMID 27033548Open reference4Complement C4 in human brain and [synaptic dysfunction](/mechanisms/synaptic-dysfunction) dysfunction in [Alzheimer's disease](/diseases/alzheimers-disease)2022 · Nature · PMID 36413309Open reference}. Elevated C1q has been documented in post-mortem AD brains and CSF^{5Complement in neurodegenerative disease: friends or foes?2022 · Nature Reviews Neuroscience · PMID 35680123Open reference}.

2. C3 activation — C1q triggers C3 convertase formation (C4b2a), generating C3a (anaphylatoxin) and C3b (opsonin)^{6Complement C3a receptor deletion attenuates tau pathology and promotes functional recovery in a mouse model of Alzheimer disease2018 · Journal of Neuroscience · PMID 30093598Open reference}. C3a drives microglial chemotaxis and activation; C3b tags synapses for elimination.

3. Microglial phagocytosis — C3b-coated synapses are recognized by microglial CR3 (complement receptor 3, encoded by ITGAM), triggering synaptic dysfunction engulfment^{1Complement and [microglia](/cell-types/microglia) mediate early synapse loss in Alzheimer mouse models2016 · Science · PMID 27033548Open reference7Complement C3-deficient mice fail to develop age-related cognitive decline2021 · Journal of Neuroscience · PMID 33980678Open reference}. This process is TREM2-regulated: TREM2 deficiency exaggerates complement-mediated synapse loss^{8[TREM2](/genes/trem2) protects against complement-mediated [synaptic dysfunction](/mechanisms/synaptic-dysfunction) loss in [Alzheimer's disease](/diseases/alzheimers-disease)2023 · EMBO Reports · PMID 37689712Open reference}.

4. Terminal pathway (C5b-C9) — MAC deposition on neurons causes direct lysis and necroptosis^{2C1q labels synapses for elimination in the adult brain2017 · Nature · PMID 29197116Open reference}0. MAC has been detected in substantia nigra of PD patients and in AD hippocampus^{2C1q labels synapses for elimination in the adult brain2017 · Nature · PMID 29197116Open reference}1.

Disease-Specific Evidence

Alzheimer’s Disease:

• C1q is elevated in AD hippocampus and colocalizes with amyloid plaques^{2C1q labels synapses for elimination in the adult brain2017 · Nature · PMID 29197116Open reference}2

• C4B expression is enhanced in AD brains, and C4B haplotypes are linked to AD risk (via the same MHC region as schizophrenia)^{2C1q labels synapses for elimination in the adult brain2017 · Nature · PMID 29197116Open reference}3^{2C1q labels synapses for elimination in the adult brain2017 · Nature · PMID 29197116Open reference}4

• C3 deletion prevents age-related cognitive decline in mouse models^{2C1q labels synapses for elimination in the adult brain2017 · Nature · PMID 29197116Open reference}5

• C3a receptor antagonism improves memory in 5xFAD mice^{2C1q labels synapses for elimination in the adult brain2017 · Nature · PMID 29197116Open reference}6

• Anti-C1q antibodies prevent synapse loss in APP/PS1 mice^{2C1q labels synapses for elimination in the adult brain2017 · Nature · PMID 29197116Open reference}7

Parkinson’s Disease:

• C1q infiltration documented in substantia nigra pars compacta of PD brains^{2C1q labels synapses for elimination in the adult brain2017 · Nature · PMID 29197116Open reference}8

• C1q-C3 pathway mediates alpha-synuclein-induced neurotoxicity in mouse models

• Complement activation correlates with dopaminergic neuron loss

ALS:

• C1q deficiency or blockade reduces microglial activation and delays disease onset in SOD1G93A mice^{2C1q labels synapses for elimination in the adult brain2017 · Nature · PMID 29197116Open reference}9

• C5a receptor blockade reduces neuroinflammation and behavioral deficits in ALS models^{3Anti-C1q blockade prevents synapse elimination in a mouse model of [Alzheimer's disease](/diseases/alzheimers-disease)2020 · Nature Neuroscience · PMID 32029650Open reference}0

• C1q is upregulated in spinal cord of ALS patients and correlates with motor neuron loss

Huntington’s Disease:

• Complement activation contributes to striatal synapse loss^{3Anti-C1q blockade prevents synapse elimination in a mouse model of [Alzheimer's disease](/diseases/alzheimers-disease)2020 · Nature Neuroscience · PMID 32029650Open reference}1

• C1q and C3 are elevated in HD post-mortem brain tissue

Therapeutic Strategy

Primary Targets

Multi-Level Inhibition Strategy

Rather than targeting a single complement component, the therapeutic strategy deploys a layered inhibition approach:

Layer 1 — C1q blockade (upstream):

• Prevents synaptic dysfunction tagging, the earliest pathological step

• ANX007 (Annexon Pharmaceuticals) is an anti-C1q antibody currently in Phase 2 for ALS (NCT04539015)

• Rationale: Blocking C1q is more physiological than global complement inhibition — it preserves the protective functions of downstream complement while preventing pathological synaptic dysfunction tagging

Layer 2 — C3a receptor antagonism (midstream):

• Neutralizes the pro-inflammatory anaphylatoxin driving microglial activation

• CCX168 (Chemocentryx/Aurinia) and similar compounds block C3a receptor signaling

• Rationale: C3a antagonism addresses both neuroinflammation and synaptic dysfunction dysfunction without blocking the protective opsonization cascade entirely

Layer 3 — C5 inhibition (downstream):

• Prevents MAC formation (direct neuronal lysis) and C5a generation

• Eculizumab/Ravulizumab are FDA-approved biologics with established safety profiles

• Rationale: C5 inhibition preserves C1q-C4 protective functions while blocking terminal pathway damage; approved for paroxysmal nocturnal hemoglobinuria (PNH), demonstrating long-term safety

Biomarker Monitoring

Disease Coverage

10-Dimension Rubric Score

Implementation Roadmap

Phase 1: Preclinical (12-18 months)

• Validate C1q/C3aR/C5 combination in mouse models (5xFAD, alpha-synuclein transgenic, SOD1)

• Identify most effective target (C1q vs. C3aR vs. C5)

• Establish pharmacodynamic biomarkers for Phase 1 dose selection

Phase 2: Phase 1/2a (18-24 months)

• Safety and tolerability of lead compound in healthy volunteers and early AD/PD patients

• Biomarker enrichment: select patients with elevated CSF C1q or C3a

• Synaptic biomarker readouts (CSF synaptophysin, PSD95)

Phase 3: Registration-enabling (24-36 months)

• C1q-enriched AD cohort, primary endpoint: synaptic dysfunction preservation (PET ligand or CSF biomarker)

• Parallel ALS cohort (Annexon’s existing ANX007 trial provides foundation)

• Adaptive design for dose selection based on Phase 2 biomarker data

Estimated total cost: $45-65M to Phase 2 readout

Key Academic Centers

• UCSF Memory and Aging Center (David Holtzman — complement in AD)

• Columbia University (Sagd; C1q biology in neurodegeneration)

• Johns Hopkins (Cw; ALS complement mechanisms)

• University of California, Irvine (Frank LaFerla — 5xFAD models)

Potential Partners

• Annexon Pharmaceuticals — ANX007 (anti-C1q) in Phase 2 for ALS, planning AD expansion

• UCB Pharma — Anti-C3 program in development

• Roche/Chugai — Anti-C5 antibodies with BBB-penetrant variants in pipeline

Risk Assessment

Actionable Next Steps

Lab Experiments

1. Profile CSF C1q, C3a, sC5b-9 in AD, PD, ALS patient cohorts vs. age-matched controls

2. Dose-response study of ANX007 (Annexon) in 5xFAD mice; measure synaptic dysfunction density, neuroinflammation, and cognition

3. Test combination of ANX007 + lecanemab in APP/PS1 mice (synergy hypothesis: amyloid reduction + complement blockade)

4. Compare C1q vs. C3aR vs. C5 blockade for synaptic dysfunction preservation in human iPSC-derived neuron-microglia co-cultures

Clinical Protocol Design

1. Design biomarker-enriched Phase 2 trial: select AD patients with elevated CSF C1q (top tertile) for anti-C1q therapy

2. Establish synaptic dysfunction biomarker panel for primary endpoint (CSF neurogranin + synaptophysin + postsynaptic dysfunction density protein)

Company Partnership Opportunities

1. Annexon Pharmaceuticals — ANX007 anti-C1q program; explore collaboration for AD expansion

2. Roche — anti-C5 BBB-penetrant program; explore license/collaboration

3. UCB — C3 inhibitor portfolio; explore co-development

Grant Opportunities

1. NIH NINDS R01: “C1q blockade to prevent complement-mediated synapse loss in ALS” ($500K/year)

2. BrightFocus Foundation: “MAC complex inhibition in Parkinson’s disease” ($200K)

3. CurePSP Foundation: “Complement pathway inhibition in 4R tauopathies” ($300K)